The Multiple Waves of Cannabinoid 1 Receptor Signaling
- PMID: 27338082
- PMCID: PMC11037448
- DOI: 10.1124/mol.116.104539
The Multiple Waves of Cannabinoid 1 Receptor Signaling
Abstract
The cannabinoid 1 receptor (CB1R) is one of the most abundant G protein-coupled receptors (GPCRs) in the central nervous system, with key roles during neurotransmitter release and synaptic plasticity. Upon ligand activation, CB1Rs may signal in three different spatiotemporal waves. The first wave, which is transient (<10 minutes) and initiated by heterotrimeric G proteins, is followed by a second wave (>5 minutes) that is mediated by β-arrestins. The third and final wave occurs at intracellular compartments and could be elicited by G proteins or β-arrestins. This complexity presents multiple challenges, including the correct classification of receptor ligands, the identification of the signaling pathways regulated by each wave, and the underlying molecular mechanisms and physiologic impacts of these waves. Simultaneously, it provides new opportunities to harness the therapeutic potential of the cannabinoid system and other GPCRs. Over the last several years, we have significantly expanded our understanding of the mechanisms and pathways downstream from the CB1R. The identification of receptor mutations that can bias signaling to specific pathways and the use of siRNA technology have been key tools to identifying which signaling cascades are controlled by G proteins or β-arrestins. Here, we review our current knowledge on CB1R signaling, with particular emphasis on the mechanisms and cascades mediated by β-arrestins downstream from the CB1R.
Copyright © 2016 by The Author(s).
Figures



Similar articles
-
Mechanisms of Biased β-Arrestin-Mediated Signaling Downstream from the Cannabinoid 1 Receptor.Mol Pharmacol. 2016 Jun;89(6):618-29. doi: 10.1124/mol.115.103176. Epub 2016 Mar 23. Mol Pharmacol. 2016. PMID: 27009233 Free PMC article.
-
Ligand-specific endocytic dwell times control functional selectivity of the cannabinoid receptor 1.Nat Commun. 2014 Aug 1;5:4589. doi: 10.1038/ncomms5589. Nat Commun. 2014. PMID: 25081814 Free PMC article.
-
Mutations in the 'DRY' motif of the CB1 cannabinoid receptor result in biased receptor variants.J Mol Endocrinol. 2015 Feb;54(1):75-89. doi: 10.1530/JME-14-0219. Epub 2014 Dec 15. J Mol Endocrinol. 2015. PMID: 25510402
-
β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia.Handb Exp Pharmacol. 2014;219:427-43. doi: 10.1007/978-3-642-41199-1_22. Handb Exp Pharmacol. 2014. PMID: 24292843 Free PMC article. Review.
-
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery.Pharmacol Ther. 2025 Mar;267:108795. doi: 10.1016/j.pharmthera.2025.108795. Epub 2025 Jan 17. Pharmacol Ther. 2025. PMID: 39828030 Review.
Cited by
-
Chlorinated Enyne Fatty Acid Amides from a Marine Cyanobacterium: Discovery of Taveuniamides L-M and Pharmacological Characterization of Taveuniamide F as a GPCR Antagonist with CNR1 Selectivity.Mar Drugs. 2023 Dec 30;22(1):28. doi: 10.3390/md22010028. Mar Drugs. 2023. PMID: 38248654 Free PMC article.
-
Circulating Endocannabinoids and Mortality in Hemodialysis Patients.Am J Nephrol. 2020;51(2):86-95. doi: 10.1159/000505444. Epub 2020 Jan 14. Am J Nephrol. 2020. PMID: 31935741 Free PMC article.
-
Retromer stops beta-arrestin 1-mediated signaling from internalized cannabinoid 2 receptors.Mol Biol Cell. 2017 Nov 15;28(24):3554-3561. doi: 10.1091/mbc.E17-03-0198. Epub 2017 Sep 27. Mol Biol Cell. 2017. PMID: 28954865 Free PMC article.
-
Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System.Molecules. 2019 Mar 6;24(5):918. doi: 10.3390/molecules24050918. Molecules. 2019. PMID: 30845666 Free PMC article. Review.
-
Cannabinoid Receptors and Ligands: Lessons from CNS Disorders and the Quest for Novel Treatment Venues.Adv Exp Med Biol. 2021;1297:43-64. doi: 10.1007/978-3-030-61663-2_4. Adv Exp Med Biol. 2021. PMID: 33537936 Free PMC article.
References
-
- Ariens EJ. (1954) Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. Arch Int Pharmacodyn Ther 99:32–49. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources